Another company has chosen to add Bitcoin (BTC) to its balance.

Christian Angermayer, chairman of Germany-based Biopharmaceutical Company Atai Life Sciences (Atai) announced today that the company would develop its own Bitcoin Treasury strategy.

“In an era of sustained inflation and unstable markets, I find myself asking an important question for biotech companies who want to preserve and optimize the capital they have: Could a part of Treasury Cash to Bitcoin help preserve, optimize and even expand a company’s runway and thus contribute to its success,” Angermayer wrote about Substack.

The company will initially invest $ 5 million in Bitcoin, Angermayer said, while having enough cash, short -term securities and public equity for operational expenses for 2027.

The pharmaceutical company is the latest in a large number of companies that have tried to repeat Michael Saylor’s Bitcoin Treasury strategy.

Atai rose briefly as the news bread but is now down 2.8% for the day. After briefly peaking $ 87,000 overnight, Bitcoin has been in Quick Retreat and now changed hands to $ 83,900, lower by approx. 1% over the last 24 hours.